Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced menopause, in women with breast cancer who are under treatment with an aromatase inhibitor.
Vaginal Atrophy in Breast Cancer Patients
DRUG: Placebo|DRUG: Prasterone (DHEA)
Change from Baseline to Week 12 in the Percentage of Superficial Cells, 12 weeks|Change from Baseline to Week 12 in the Percentage of Parabasal Cells, 12 weeks|Change from Baseline to Week 12 in Vaginal pH, 12 weeks|Change from Baseline to Week 12 in Moderate/Severe VVA symptom being Most Bothersome (MBS), 12 weeks
Change from Baseline to Week 12 in Moderate/Severe VVA symptom (not most bothersome), 12 weeks|Change from Baseline to Week 12 on arousal/lubrication domain of Female Sexual Function Index (FSFI) questionnaire, Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor., 12 weeks|Change from Baseline to Week 12 on subjective arousal domain of FSFI, Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor., 12 weeks|Change from Baseline to Week 12 on desire domain of FSFI, Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor., 12 weeks|Change from Baseline to Week 12 on satisfaction domain of FSFI, Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor., 12 weeks|Change from Baseline to Week 12 on orgasm domain of FSFI, Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor., 12 weeks|Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions, Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy., 12 weeks|Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness, Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy., 12 weeks|Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity, Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy., 12 weeks|Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color, Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy., 12 weeks
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced menopause, in women with breast cancer who are under treatment with an aromatase inhibitor.